China-based 3SBio Inc. (HKG: 1530) has entered into a strategic partnership with Duality Biologics, a leading antibody conjugate drug (ADC) developer with operations in the United States and China. The collaboration centers on the licensing rights to Duality Biologics’ promising ADC, DB-1303, which targets the HER2 protein.
Agreement Details
Pursuant to the agreement, 3SBio secures the commercialization rights to DB-1303 for multiple indications across mainland China, Hong Kong, and Macau. In return, Duality Biologics will receive an undisclosed upfront payment, as well as development and sales milestone payments. Duality Biologics will maintain responsibility for the ongoing clinical development and regulatory filings of DB-1303 within the specified territories, ensuring the product’s progress towards market readiness.-Fineline Info & Tech
